相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Predictors of venous thromboembolism recurrence and the bleeding events identified using a Japanese healthcare database
Mashio Nakamura et al.
JOURNAL OF CARDIOLOGY (2017)
Vascular Toxicities of Cancer Therapies The Old and the New - An Evolving Avenue
Joerg Herrmann et al.
CIRCULATION (2016)
Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions
Zhexuan Lin et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2016)
Antiangiogenic therapy in oncology: current status and future directions
Gordon C. Jayson et al.
LANCET (2016)
Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC A Meta-Analysis
Zhenguang Chen et al.
MEDICINE (2015)
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
Shaodong Hong et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis
Wei-Xiang Qi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: An updated systematic review and comparative meta-analysis
Omar Abdel-Rahman et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis
Omar Abdel-Rahman et al.
FUTURE ONCOLOGY (2014)
Biotherapies in metastatic colorectal cancers in 2014
Anne Jouinot et al.
PRESSE MEDICALE (2014)
Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis
Ling Peng et al.
TUMOR BIOLOGY (2014)
Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials
Guru Sonpavde et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies
Austin Duffy et al.
HEPATOLOGY (2013)
Risk of venous thromboembolic events associated with VEGFR-TKIs: A systematic review and meta-analysis
Wei-Xiang Qi et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Impact of double-blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta-analysis
J. -C. Lega et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Influence of Reported Study Design Characteristics on Intervention Effect Estimates From Randomized, Controlled Trials
Jelena Savovic et al.
ANNALS OF INTERNAL MEDICINE (2012)
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis
J. Cortes et al.
ANNALS OF ONCOLOGY (2012)
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis
Sonal Singh et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2011)
Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials
Xiao Feng Hang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies
Herbert I. Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Noncardiac Vascular Toxicities of Vascular Endothelial Growth Factor Inhibitors in Advanced Cancer: A Review
Dorothy Keefe et al.
ONCOLOGIST (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials
Vishal Ranpura et al.
ACTA ONCOLOGICA (2010)
Minimizing Bias in Randomized Trials The Importance of Blinding
Bruce M. Psaty et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials
Sabine Geiger-Gritsch et al.
ONCOLOGIST (2010)
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
Youjin Je et al.
LANCET ONCOLOGY (2009)
Hemostatic complications of angiogenesis inhibitors in cancer patients
Francesca Elice et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients A Meta-analysis
Shobha Rani Nalluri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes:: meta-epidemiological study
Lesley Wood et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
Frank A. Scappaticci et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Michael J. Bradburn et al.
STATISTICS IN MEDICINE (2007)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research
JAC Sterne et al.
STATISTICS IN MEDICINE (2002)
Systematic reviews in health care -: Assessing the quality of controlled clinical trials
P Jüni et al.
BMJ-BRITISH MEDICAL JOURNAL (2001)
Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor
I Zachary
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2001)
分享论文
